The United States Food and Drug Administration (USFDA) has conducted an inspection at Gland Pharma’s API Facility at JNPC, Visakhapatnam from January 23, 2023 to January 27, 2023 and has been completed with Zero observations.
Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.